The modification of proteins by SUMO (small ubiquitin-related modifier) conjugation is becoming increasingly recognized as an important regulatory event. Protein SUMOylation can control a whole range of activities, including subcellular localization, protein-protein interactions and enzymatic activity. However, the SUMOylation process can itself be controlled. In the present review, the mechanisms through which protein SUMOylation is regulated are discussed, with particular emphasis on the impact of signalling pathways. A major point of regulation of the SUMO pathway is through targeting the E3 ligases, and a number of different ways to achieve this have been identified. More generally, the MAPK (mitogen-activated protein kinase) pathways represent one way through which SUMOylation of specific proteins is controlled, by using molecular mechanisms that at least in part also function by modifying the activity of SUMO E3 ligases. Further intricacies in signalling pathway interactions are hinted at through the growing number of examples of cross-talk between different post-translational modifications and SUMO modification.
Introduction
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dependent SUMOylation motif) (characterized by clusters of acidic residues in the downstream region) [5] . These extended motifs provide further specificity and enhanced intrinsic propensities for SUMOylation. Further variations on these motifs can impart regulatory properties (see below). However, while most of the substrates contain the core KXE motif, a significant number do not, and in those cases, other structural constraints are thought to be important.
The functions attributed to SUMO modification differ significantly from those identified for ubiquitin, which predominantly targets proteins for degradation. Indeed, SUMO modification has been shown to exhibit a number of disparate functions depending on the protein substrates (reviewed in [1, 2, 6] ). One of the major roles emerging for SUMOylation is in controlling the output from transcriptional regulatory proteins, and in particular in mediating transcriptional repression (reviewed in [7] ). However, roles in recombination, DNA repair and a growing number of cytoplasmic processes have been uncovered (reviewed in [6] ).
Protein SUMOylation is not a static process. Indeed SUMOylation appears very dynamic, with typically only a small proportion of any protein being modified. The latter observation has been suggested to equate to a role of SUMO in establishing a particular state that is then maintained through the action of other proteins and/or modifications (reviewed in [1] ). Dynamic SUMOylation is observed in many situations, but is clearly demonstrated during circadian clock control where cyclical SUMOylation of BMAL1 (brain and muscle Arnt-like protein-1) parallels its rhythmic activation [8] . A number of ways of regulating protein SUMOylation have been discovered (reviewed in [9] ). Here, we describe some of the latest advances in this area, with a particular focus on the role of signalling pathways in the regulation of E3 ligases and the role of MAPK (mitogen-activated protein kinase) pathways in controlling protein SUMOylation status.
Global mechanisms for SUMOylation control
Protein SUMOylation can be regulated in a substrate-specific manner (see below) or in a more global way. Typically, global SUMOylation is controlled by targeting one of the core SUMO pathway components. However, control exerted over the whole pathway has also been observed. For example, studies in keratinocytes demonstrated that the whole SUMO pathway is transiently up-regulated during differentiation, thereby causing changes in the global patterns of protein SUMOylation [10] . It is also well documented that various stress stimuli cause changes in global SUMOylation patterns (reviewed in [9] ). For example, various cellular stresses, including heat shock, cause global increases in SUMOylation in mammalian cells [11] . Conversely, reductions in global SUMOylation levels can be seen and one way this is achieved is through targeting the E2 enzyme Ubc9. Low doses of H 2 O 2 cause the reversible oxidation of the E2-conjugating enzyme Ubc9 [12] . This oxidation event inactivates Ubc9 and causes a global decrease in SUMOylation levels. Similar reductions in global SUMOylation levels are seen upon infection with the CELO (chicken embryo lethal orphan) adenovirus, and this effect can be attributed to the Gam1 protein, which targets the E1 activating enzyme SAE1/SAE2 and the E2 Ubc9 for destruction [13] . In the case of viral infection, the loss of SUMOylation is thought to benefit the virus due to the resulting de-repression of many transcriptional processes, thereby providing a permissive environment for viral propagation.
MAPK pathways and regulation of SUMOylation
One way in which SUMOylation can be controlled is through the action of protein kinase cascades in response to extracellular signals. In particular, such cascades potentially provide specificity to controlling the SUMOylation of a limited number of substrates under defined conditions. The MAPK pathways are a common route through which extracellular signals are transduced into intracellular responses (reviewed in [14] . As SUMOylation levels decrease, Elk-1 phosphorylation increases and permits Elk-1 to go from a transcriptionally repressive to a transcriptionally active form. However, the link between MAPK activation and Elk-1 de-SUMOylation remains obscure. More recently, the E3 ligase PIAS [protein inhibitor of activated STAT (signal transducer and activator of transcription)] xα has been implicated in controlling this switch but appears to do so independently of its SUMO ligase activity [16] .
A growing number of links are now being made between the MAPK pathways and protein SUMOylation. For example, treatment of cells with 17β-oestradiol causes up-regulation of the ERK MAPK pathway and enhanced phosphorylation of the co-activator protein AIB1 (amplified in breast cancer 1) {also known as RAC3 (receptor-associated co-activator 3), ACTR (activator of thyroid and retinoic acid receptors), SRC-3 (steroid receptor co-activator 3) and p/CIP [p300/CBP (cAMP-response-element-binding protein-binding protein)]}. This phosphorylation inversely correlates with AIB1 SUMOylation, and mutational analysis suggests mutual cross-regulation of phosphorylation and SUMOylation [17] . It is however unclear how this occurs at the molecular level as the SUMOylation sites are not close to the phosphorylation sites in the primary sequence.
In contrast with the role of MAPK pathways in promoting de-SUMOylation, it is also feasible that they might also promote SUMOylation under some circumstances. Indeed, recently, we have studied the role of ERK MAPK signalling in potentially controlling SUMOylation of the ETSdomain transcription factor PEA3 (polyoma enhancer activator 3) and found that ERK signalling promotes PEA3 SUMOylation (B. Guo and A.D. Sharrocks, unpublished work). Furthermore, SUMOylation appears to promote transcriptional activation by PEA3; thus ERK signalling can enhance the transactivation capacity of different ETS-domain transcription factors through modifying their SUMOylation status in an opposite manner (Figure 2 ). In the case of Elk-1, loss of repressive SUMO enhances transactivation, but for PEA3, increases in activating SUMO modifications cause the same molecular effect, thereby providing two different modes of regulatory logic to reach the same endpoint.
Intriguingly, one of the first suggestions of a link between MAPK signalling and the regulation of SUMOylation was the observation that p38 signalling led to the increased Smad4 SUMOylation [18] . This increase in SUMOylation was thought to be due to the up-regulation of the SUMO E3 ligase PIASxβ at the transcriptional and protein levels. In addition to increasing the levels of PIASx proteins, p38 signalling has also been directly implicated in modifying the activity of these proteins [19] . These additional links between the p38 pathway and E3 ligases were made during a study of the effect of stress signalling on Elk-1 SUMOylation levels. Whereas mitogenic signalling via the ERK MAPK pathway causes de-SUMOylation, stress signalling via the p38 pathway does not cause de-SUMOylation although Elk-1 still becomes phosphorylated [19] . Interestingly, the E3 ligase PIASxα plays a key role in both cases. Whereas PIASxα promotes de-SUMOylation in response to ERK pathway signalling, PIASxα is required to maintain Elk-1 SUMOylation upon p38 pathway activation. The switch between these two modes of operation is through p38-mediated phosphorylation of PIASxα. Thus PIASxα acts as a molecular rheostat that controls the transcriptional activation output from Elk-1 by either facilitating loss or promoting retention of the repressive SUMO modification, depending on the pathway that is activated.
Thus a common theme seems to be the involvement of E3 ligases in controlling SUMOylation in the response to signalling pathway activation.
E3 ligases as a focal point for regulation?
Unlike the ubiquitin pathway where multiple E2 proteins exist, there is only a single E2 ligase in the SUMO pathway. Thus any regulation of Ubc9 is likely to produce a global response, as illustrated in the case of regulating Ubc9 activity by H 2 O 2 [12] . Thus the E3 ligases represent an attractive point for potential regulation. It is currently unclear how many E3 ligases exist, but to date several have been identified including PIASxα, PIASxβ, PIAS1, PIAS3, PIASy, RanBP2 (Ran-binding protein 2), Pc2 and HDAC4 (histone deacetylase 4) (reviewed in [1, 20] ). Several recent studies have implicated these proteins as points for regulation.
NEMO (NF-κB essential modulator) is a regulator of NF-κB (nuclear factor κB) activity, and NEMO itself is SUMOylated in response to genotoxic agents, which in turn leads to NF-κB activation. Recently, PIASy was identified as the SUMO E3 ligase for NEMO, and genotoxic stress promotes the interaction of NEMO and PIASy [21] . Thus an important regulated interaction between a substrate and an E3 ligase has been defined, although it is currently unclear how genotoxic stresses promote this interaction.
Another E3 ligase Pc2 has also been shown to be regulated in response to DNA-damaging agents [22] . In this case, direct molecular links have been established whereby HIPK2 (homeodomain-interacting protein kinase 2) is activated following DNA damage, and this then phosphorylates Pc2. The E3 ligase activity of phosphorylated Pc2 is enhanced and one target is HIPK2 itself, and SUMOylation promotes the ability of HIPK2 to act as a transcriptional repressor. This provides a nice example of a feedback loop where mutual regulatory modifications (SUMOylation and phosphorylation) are exchanged between Pc2 and HIPK2.
Further interactions between signalling pathways and E3 ligases have been made with PIAS1, which is a direct target of IKKα [IκB (inhibitor of NF-κB) kinase α] following exposure of cells to pro-inflammatory stimuli [23] . Phosphorylation of PIAS1 promotes its ability to associate with promoters and reduce the binding of other transcription factors including STAT1 and NF-κB. Complex interactions between SUMOylation and phosphorylation are suggested by the observation that the E3 ligase activity of PIAS1 is needed for phosphorylation by IKKα. However, the intrinsic ligase activity of PIAS1 is not affected by phosphorylation. This has several parallels with the Elk-1-PIASx interaction where the SUMO E3 ligase is a target of a stress-activated signalling pathway and the functional output is in promoting or inhibiting other binding events at the promoter rather than being dependent on global changes in the E3 ligase activity [19] .
A third class of E3 ligase, RanBP2, is also subject to regulatory phosphorylation. In this case, CDKs (cyclindependent kinases) act upon RanBP2 during the cell cycle, but the functional consequences of this phosphorylation event are currently unknown [24] . Furthermore, signalling through the PKB (protein kinase B; also called Akt) pathway leads to up-regulation of RanBP2 levels [25] , suggesting that RanBP2 is also subject to regulation at multiple levels.
Cross-talk between SUMO and other post-translational modifications
SUMOylation takes place on lysine residues, which can also be modified by other post-translational modifications, including acetylation, methylation and ubiquitination. This provides ample opportunity for regulatory cross-talk between different pathways that culminate in different modification events. Indeed several early studies on the SUMO pathway highlighted the direct antagonism that exists for SUMOylation and ubiquitination of the same residues in IκBα [26] . Similarly, in PCNA (proliferating-cell nuclear antigen), dynamic switching between SUMOylation and ubiquitination of the same residues has been observed [27] . More recently, acetylation has been shown to antagonize SUMOylation of the same lysine residues in substrates such as MEF2 (myocyte enhancer factor 2) [20, 28] and HIC-1 (hypermethylated in cancer 1) [29] . Moreover, in the case of MEF2, phosphorylation appears to be a direct trigger that permits switching between acetylated and SUMOylated states [28] . Phosphorylation of MEF2 takes place on a serine residue located three amino acids downstream from the core SUMOylation motif, and phosphorylation promotes SUMOylation [28, 30, 31] . The kinase thought to be involved in this switch is CDK5, which recognizes the core SP motif [30] , and phosphorylation is reversed by the phosphatase calcineurin [28] . A similar phosphorylation-dependent switch controlling SUMOylation levels was also identified in HSF-1 (heat-shock factor 1) [32] and led to the identification of a panel of potential SUMO substrates that contain this extended motif, KXEXXSP, and was named the PDSM (phosphorylation-dependent SUMOylation motif) (reviewed in [33] ). Importantly, this motif is related to the NDSM, as it appears that it is the negative charge imparted by the phosphorylation event that is a key determinant in enhancing substrate SUMOylation. Thus two types of substrates can be identified in which SUMOylation is constitutively enhanced due to the presence of an NDSM, or inducibly controlled through the PDSM. A further variation on this theme was suggested from work on HIC-1, where the proline residues in the core motif, KXEP, were shown to be important in controlling the acetylation-SUMOylation switch on the lysine residue [29] . Thus different extended SUMO motifs impart different regulatory potential to the SUMOylation process.
The above examples therefore illustrate the potential for regulatory cross-talk between different pathways and, in the case of MEF2, direct links to cellular signalling pathways have been made whereby these pathways control substrate SUMOylation through controlling substrate phosphorylation levels.
Perspectives
Our current view of SUMOylation is evolving from one in which SUMO is a static modification or one that is cycled as a default mechanism to one where, in many cases, substrate SUMOylation is controlled by signalling pathways. This control can be exerted directly through phosphorylation-dependent switches on the substrate or indirectly through control of the SUMO pathway itself. One key area for regulation appears to be through the E3 ligases, but equally regulation might occur at the level of the SUMO proteases and this is likely to be an area for future studies.
The MAPK pathways have been linked to controlling protein SUMOylation of several substrates, and it is tempting to speculate that in some cases, novel direct regulatory links will be made through the PDSM, KXEXXSP, as the SP motif corresponds to the consensus site for this class of kinase. Reciprocally, links between the SUMO pathway and MAPK pathway activity can be envisaged as demonstrated by the stimulatory effect that PIAS1 has on the JNK MAPK pathway [34] .
More recent discoveries such as the observation that the protein tyrosine phosphatase PTP1B is regulated by SUMOylation [35] suggest even more complex reciprocal links between SUMOylation and signalling pathways. Indeed, previous studies have demonstrated that the MAPK pathway component MEK-1 (MAPK/ERK kinase 1) is SUMOylated in Dictyostelium and this SUMOylation event is also regulated by MEK-1 phosphorylation by upstream kinases [36] . In addition to classical signalling pathways, nuclear hormone receptors can also influence the output of signalling cascades by transrepression activity at promoters. Ligand-dependent SUMOylation of nuclear hormone receptors LXR (liver X receptor) and PPARγ (peroxisome-proliferator-activated receptor γ ) enhances their transrepressive properties and inhibits the expression of genes that are usually responsive to inflammatory signalling [37, 38] . Thus, depending on the inflammatory signals and nuclear hormone ligands present, then ultimately the SUMOylation levels of nuclear hormone receptors control the overall transcriptional response of the cell.
Future studies will undoubtedly uncover more intricacies in the links between intracellular signalling pathways and SUMOylation control. Potentially, these links may identify important areas that could be targeted for therapeutic intervention in diseases such as cancer where signalling pathway wiring is often disrupted.
